AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors

被引：0
|
作者：
Dowlati, A. [1 ]
Richardson, D. L. [2 ]
Lorusso, P. [3 ]
Spira, A. I. [4 ]
Bashir, B. [5 ]
Hirmand, M. [6 ]
Mehta, M. [6 ]
Patel, M. R. [7 ]
机构：
[1] Case Western Reserve Univ, Div Hematol & Oncol, Dept Med, Cleveland, OH USA
[2] Univ Oklahoma, Gynecol Oncol Sect, Dept Obstet & Gynecol Sect Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Yale Univ, Dept Med Oncol, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT USA
[4] Virginia Canc Specialists, VCS Res Inst, Fairfax, VA USA
[5] Thomas Jefferson Univ, Div Solid Tumors, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Avenzo Therapeut Inc, Clin Dev, San Diego, CA USA
[7] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439TiP
引用
收藏
页码：S405 / S405
页数：1
相关论文
共 50 条
  • [1] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [2] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [4] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    CANCER RESEARCH, 2024, 84 (07)
  • [5] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours
    Powderly, J.
    Bendell, J. C.
    Carneiro, B. A.
    Italiano, A.
    Macarulla Mercade, T.
    Castanon Alvarez, E.
    Imbimbo, M.
    Massard, C.
    Mueller, N.
    Gasco-Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S728 - S729
  • [8] A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
    Gutierrez, M.
    Garralda, E.
    Calvo, E.
    van Dongen, M.
    Eskens, F. A.
    Finlay, M.
    Menas, F. Z.
    Zhu, C.
    Wu, M.
    Guillemin-Paveau, H.
    Abbadessa, G.
    Perez, R.
    Yildirim, O.
    Naing, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S646 - S647
  • [9] First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors
    Dulloo, S.
    Fennell, D. A.
    Szlosarek, P. W.
    Thistlethwaite, F.
    Lord, S.
    Rahman, N. M.
    Greystoke, A.
    Cunniff, B.
    Dzialo, J.
    Poile, C.
    Panchal, R.
    Duncan, J.
    Graham, P.
    Bexon, A. S.
    Naumov, G.
    Spicer, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1292 - S1293
  • [10] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345